HRAS and cancer: However, HRAS mutations are rarely seen in human cancers (4%), and whether romidepsin also inhibits transformation caused by the Ras isoforms most commonly mutated in human cancers (KRAS and NRAS; 21 and 8%, respectively [18]) has not yet been addressed.